NASDAQ : NBTX

Nanobiotix S.A. — Company profile

Healthcare · Biotechnology · France

Last price 33.8 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.71B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Details

NameNanobiotix S.A.
SectorHealthcare
IndustryBiotechnology
Employees98
Founded2003
Ipo Date2020-12-11
CeoLaurent Levy
CountryFrance
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyEUR
Ipo Price13.50
IsinUS63009J1079
Cusip63009J107
Cik1760854
Sic2834

Key executives

NameTitle
Dr. Laurent Levy Ph.D.Co-Founder, President of the Executive Board and Chief Executive Officer
Anne-Juliette Hermant M.A.Chief People Officer and Member of Executive Board
Dr. Louis Kayitalire M.D.Chief Medical Officer and Member of Executive Board
Earl J. Bergey Ph.d.Co-Founder
Arnd Christ MBAChief Financial Officer and Member of Executive Board
Brandon OwensVice President of Strategic Marketing and Corporate Communication
Margaret GalluzziVice President and Global Head of Clinical Operations
Dr. Leonard A. Farber M.D.Chief Clinical and Medical Affairs Officer and Chairman of the Scientific Advisory Board
Anne-Sophie LariviereChief Product Innovation and Delivery Officer

Contact

Address60 rue de Wattignies, Paris, 75012, France
Phone33 1 40 26 04 70
Websitehttps://www.nanobiotix.com